• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Purple Biotech Ltd. - American Depositary Shares (NQ:PPBT)

    3.830 -0.180 (-4.49%)
    Streaming Delayed Price Updated: 1:32 PM EDT, Mar 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Purple Biotech Ltd. - American Depositary Shares

    < Previous 1 2 3 Next >
    News headline image
    Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Regains Compliance with Nasdaq
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces CEO Transition
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Plan to Implement ADS Ratio Change
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Pricing of Up To $18 Million Public Offering
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Appoints Shai Lankry as Chief Financial Officer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
    From Purple Biotech Ltd.
    Via GlobeNewswire
    News headline image
    Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares
    From Purple Biotech Ltd.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.